TNGX

Rating sellAI Memo

Tango Therapeutics

As of 2026-03-07/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-03-07 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

sell

Confidence

medium

Horizon

—

Key catalyst

Partnership, licensing, or M&A interest • 2026-06-05

Expected move: -28%

Biggest risk

Clinical setbacks, dilution from capital raises, or downward analyst revisions push the stock toward the low analyst bounds and materially below current levels.

Invalidation

Break below $10 or thesis failure.

What would change my mind?

Successful positive clinical readouts and/or a strategic partnership/acquisition drive re-rating toward the high end of analyst dispersion; execution accelerates revenue pathway and reduces binary risk.

Research note

Recommendation

sell

Confidence

medium

As of

2026-03-07

Base target

$16

p=55%

Bull target

$27

p=15%

Bear target

$10

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term analyst target revisions and sentiment
Pipeline clinical-data readouts or milestone updates
Successful positive clinical readouts and/or a strategic partnership/acquisition drive re-rating toward the high end of analyst dispersion; execution accelerates revenue pathway and reduces binary risk.

BearKey bullets

Analyst downgrades or consensus target cuts
Equity dilution from financing needs
Regulatory setbacks or safety concerns

WatchKey bullets

Partnership, licensing, or M&A interest

Summary

High-level snapshot

Recommendation

sell

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $16 (p=55%)

Bull/Bear spread: +25% / -53%

Vs latest close: Bull +25% · Base -28% · Bear -53%

Scenario probabilities

Bull Target: $27 (p=15%)Base Target: $16 (p=55%)Bear Target: $10 (p=30%)

Commentary

Sentiment is mixed: analyst targets cluster in the mid‑teens while a subset of higher outliers creates dispersion and episodic volatility [#SERP-3]. The analyst median sits below the current anchor, implying limited near‑term upside absent positive trial or partnership news [#SERP-1]. Overall tone is cautious; the stock remains highly sensitive to binary clinical and funding catalysts [#SERP-5].

As of 2026-03-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Clinical setbacks, dilution from capital raises, or downward analyst revisions push the stock toward the low analyst bounds and materially below current levels.

Drivers

Scannable catalysts and supporting factors

Near-term analyst target revisions and sentiment
Pipeline clinical-data readouts or milestone updates

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-03-07Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$15.50

Range (USD)

$10.10 - $26.88

Count

Query: Tango Therapeutics Inc Common (TNGX) analyst consensus price target high low average

Tango Therapeutics (TNGX) Stock Forecast & Price Target
Search result #1
According to projections from 9 analysts, the average 12-month price target for Tango Therapeutics is 15.67 USD, with a high estimate of 19 USD and a low ...
Extracted: $15.67, $19.00Open source
Tango Therapeutics (TNGX) Stock Forecast: Analyst Ratings ...
Search result #2
Financial analysts have set a price target of $15.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated ...
Extracted: $15.50Open source
Tango Therapeutics (NASDAQ:TNGX) Price Target Raised to ...
Search result #3
... analysts' consensus is a "Moderate Buy" with a $17.86 average target. The stock traded up about 36% to open at $16.80 on Friday, giving Tango ...
Extracted: $17.86, $16.80Open source21 hours ago
Tango Therapeutics, Inc.: Target Price Consensus and Analysts ...
Search result #4
Analysts' Consensus ; Mean consensus. BUY ; Number of Analysts. 11 ; Last Close Price. 12.35USD ; Average target price. 15.67USD ; Spread / Average Target. +26.86%.
Extracted: $12.35, $15.67Open source
Tango Therapeutics, Inc. (TNGX) Price Targets
Search result #5
The forecasts for Tango Therapeutics, Inc. (TNGX) range from a low of $13 to a high of $19. The average price target represents a increase of $26.88 from the ...
Extracted: $13.00, $19.00, $26.88Open source
Tango Therapeutics, Inc. (TNGX) Analyst Ratings, Estimates ...
Search result #6
See Tango Therapeutics, Inc. (TNGX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Open source

Scenarios

Bull Target (Scenario probability)

$27 / p=15% prob

Base Target (Scenario probability)

$16 / p=55% prob

Bear Target (Scenario probability)

$10 / p=30% prob

Price $22 as of 2026-06-02

Nearest Scenario: Bull (∆ 25%)

Targets vs latest close: Bull +25% · Base -28% · Bear -53%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-05
Partnership, licensing, or M&A interest
Potential partnership or acquisition interest could surface within months; no public window disclosed, assumed conservative near-term window end for modeling purposes (assumption noted) [#SERP-3].
Prob 10.00% • Move 80.00% • Priced-in 5.00%

Short-term Catalysts

Next few weeks

Near-term analyst target revisions and sentiment
2026-06-05
Recent analyst activity and target updates (e.g., MarketBeat note and consensus pages) may drive price re-rating over the next quarter; watch for further target updates and notes that could lower consensus toward the median [#SERP-3], [#SERP-1].
Prob 60% • Move -15% • Priced-in 40%

Long-term Catalysts

Months to a year

Pipeline clinical-data readouts or milestone updates
2027-03-07
Positive late-stage or exploratory trial readouts and milestone progress would materially re-rate value over a longer horizon; absence or negative outcomes would amplify downside risk (biotech binary) [#SERP-5].
Prob 30% • Move 60% • Priced-in 20%

Risks

Analyst downgrades or consensus target cuts
Equity dilution from financing needs
Regulatory setbacks or safety concerns
Trial readout failure or delay that derates valuation

Peers

Symbol	Summary
CRSP	Complementary oncology biotech with emphasis on targeted therapies; similar binary clinical-readout risk.
BEAM	Early-stage precision-medicine company; peer for collaboration and platform valuation comparisons.
IMVT	Smaller-cap oncology developer with comparable dependency on pipeline catalysts and partner deals.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Tango Therapeutics Inc Common (TNGX) analyst consensus price target high low average
Analysis date: 2026-03-07

AI Stock Memo: TNGX - Tango Therapeutics - RankAlpha